Redox deracemization of α-substituted 1,3-dihydroisobenzofurans
作者:Xiaohan Chen、Ran Zhao、Ziqiang Liu、Shutao Sun、Yingang Ma、Qingyun Liu、Xia Sun、Lei Liu
DOI:10.1016/j.cclet.2021.02.021
日期:2021.7
However, catalytic asymmetric approaches have been rarely developed. Here, a redox deracemization technology is adopted to address the catalytic asymmetric synthesis. A broad range of α-aryl substituted 1,3-dihydroisobenzofurans are effectively deracemized in high efficiency with excellent ee. α-Alkynyl substituted ethers were also compatible with the deracemization technology.
Enantioselective Transfer Hydrogenation of Oxocarbenium Ions Enables Asymmetric Access to α-Substituted 1,3-Dihydroisobenzofurans
作者:Xigong Liu、Lei Liu、Likai Zhou、Kuiyong Jia
DOI:10.1055/a-1643-8526
日期:2022.1
Reported here is an efficient enantioselective transfer hydrogenation of cyclic oxocarbenium ions generated in situ through collapse of the corresponding acetal substrates. The asymmetric approach provides straightforwardaccess to a variety of chiral α-aryl substituted 1,3-dihydroisobenzofurans in high yields with excellent enantioselectivities. α-Alkynyl substituted 1,3-dihydroisobenzofurans were
A New Type of Chiral Sulfinamide Monophosphine Ligands: Stereodivergent Synthesis and Application in Enantioselective Gold(I)-Catalyzed Cycloaddition Reactions
A simple, newtype of chiralsulfinamidemonophosphines, the so‐called Ming‐Phos ligands, is reported; these ligands could be easily prepared from inexpensive and commercially available starting materials. The Ming‐Phos ligands performed well in the enantioselectivegold‐catalyzed cycloadditionreaction of 2‐(1‐alkynyl)‐alk‐2‐en‐1‐ones with nitrones. Both enantiomers of the products could be obtained
Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).
Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).